INDICATION AND IMPORTANT SAFETY INFORMATION
TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.  ...More

Inspiratory Flow Profiles for Dispersion of PulmoSphere™ Particles1

In a clinical study, patients with moderate to severe disease
(6 years and older) were able to receive medication via the Podhaler device2

Older patients with significant disease progression and associated decreases in forced expiratory volume in 1 second (FEV1), and younger patients (aged >6 years) with inhaled volumes <1 L, were able to generate the inspiratory flow rates and volumes required to receive their medication when following the Instructions for Use; however, no pediatric patients aged 6 to 10 years with FEV1 <40% predicted were evaluated.2

Inspiratory flow profiles of 96 patients with CF with varying degrees of lung disease from a simulated inhaler study1,3,*,†

*This study explored inspiratory variables of 96 patients with CF aged ≥6 years with varying degrees of lung disease while inhaling through mouthpieces with resistance that simulated dry-powder inhaler devices. Enrolled patients were aged 6 to 53 years with FEV1 19% to 126% predicted. TOBI® Podhaler® is indicated for patients with an FEV1 25% to 80% predicted.1-3

A flow rate of 40 L/min represents a flow rate more than 2 standard deviations below the mean peak inspiratory flow rates measured for pediatric patients in the study.4

A centralized support and access program for TOBI® Podhaler® patients

Learn more

SET TREATMENT EXPECTATIONS

Inform your patients about what to expect while taking TOBI® Podhaler®

Learn more

ADMINISTRATION INFORMATION

Administration information and helpful tips for patients taking TOBI® Podhaler®

Learn more

Share

To share this website with other health care professionals, please choose your email service provider:

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in
1 second
(FEV1) <25% or >80% predicted, or patients colonized with Burkholderia cepacia.